Ted Okon, MBA: We’re talking about Abacus, ICER (Institute for Clinical and Economic Review), NCCN (National Comprehensive Cancer Network), and ASCO (American Society of Clinical Oncology). What is that? Drug, drug, drug, and drug. I know it’s really popular in the press to slam the [drug] companies and to focus on the drug price. The drug price is an issue. Of all the components of care, it is the most rapidly growing.
But, it’s so refreshing to hear from someone who’s getting the calls every day about what’s happening and stating that it’s a larger picture than just the drug. If you look at it at the end of the day, it’s not just about an Abacus tool, or an ASCO tool, or an NCCN or ICER tool. It’s about what’s really important to patients—yes, the drug is important, but it’s these other costs, as well.
James Gilroy: I fully agree with that. What I’ll say about the Evidence Blocks is that NCCN, as an organization, has really built an amazing brand on evidence. That’s what that organization has done over time.
The domains around the Evidence Blocks—the efficacy, the safety, the quality of evidence, the consistency of evidence—a lot of that they’ve done already, and they’ve been able to sort of provide guidance to the practicing community around what guidelines should look like relative to those things. I think the Evidence Blocks is the addition of that fifth component, which is affordability.
This is really done with a very myopic focus on drug cost. I think that while I stated the brand’s been built around evidence, I think the evidence and the methodology behind how you get to affordability in these Evidence Blocks is still relatively misunderstood—at least to me and a number of my colleagues—as to what they say and then, ultimately, the process for getting there and how many boxes ultimately wind up getting shaded in.
For the most part, if you compare that to [the] acquisition cost of the drug relative across the blocks that they’ve released, I think you see relative consistency—but there are outliers. And, again, I think it’s somewhat a narrow way to try and prescribe that fifth block and say, “This is what it represents affordability-wise to any one specific patient.”
What I really like is the intent for that discussion. It is not a calculator that ultimately spits out one number and says, “You should look at this particular patient” or “You’re not going to be able to afford this product.” There's a number of things that that conversation ultimately can drive to. If there’s a low ranking on affordability, meaning that the product is particularly expensive, let’s talk about co-pay assistance. Let’s talk about patient assistance programs and the generous programs that a number of companies provide. Let’s enhance that conversation, making sure that it’s happening. Not all the way to Dr. Kolodziej’s point around calculation of net health benefit, but a step in that direction.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Initiating BP Medication Linked to Higher Fall, Fracture Risks in Nursing Home Residents
May 2nd 2024Among over 60,000 nursing home residents who initiated antihypertensive medication, rates of excess fractures due to falls per 100 person-years were as high as 5 among certain patient groups, such as those with dementia and high blood pressure (BP).
Read More
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen